Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Upgraded by Wall Street Zen

Autolus Therapeutics (NASDAQ:AUTL) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other equities analysts have also recently issued research reports about the stock. Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Finally, Weiss Ratings cut shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Autolus Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $8.75.

Autolus Therapeutics Stock Performance

AUTL opened at $2.11 on Friday. The company has a market cap of $561.60 million, a price-to-earnings ratio of -1.94 and a beta of 2.07. Autolus Therapeutics has a one year low of $1.17 and a one year high of $2.52. The business’s fifty day moving average is $1.59 and its two-hundred day moving average is $1.54.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. The business had revenue of $26.22 million during the quarter, compared to analysts’ expectations of $26.27 million. Autolus Therapeutics had a negative return on equity of 128.59% and a negative net margin of 311.98%. On average, analysts predict that Autolus Therapeutics will post -0.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Marex Group plc purchased a new position in shares of Autolus Therapeutics during the 2nd quarter worth $28,000. Independent Advisor Alliance purchased a new stake in shares of Autolus Therapeutics in the fourth quarter valued at $28,000. GAMMA Investing LLC increased its stake in Autolus Therapeutics by 115.6% in the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after purchasing an additional 8,309 shares during the last quarter. SmartHarvest Portfolios LLC acquired a new position in Autolus Therapeutics in the fourth quarter valued at $43,000. Finally, Waverly Advisors LLC purchased a new position in Autolus Therapeutics during the first quarter worth about $37,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.